Mondelez's Q4 earnings showed cost struggles, disappointing revenue, and declining profit margins, with concerning ...
HLS Therapeutics has the go ahead from the Toronto Stock Exchange to buy back up to 6.9% of its public float of shares over the next 12 months. The Canadian pharmaceutical company said Thursday it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback